<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02193230</url>
  </required_header>
  <id_info>
    <org_study_id>RC14_0073</org_study_id>
    <nct_id>NCT02193230</nct_id>
  </id_info>
  <brief_title>Taking Into Account the Patient/Parent Preference in the Galenic Choice in Atopic Dermatitis. Feasibility and Impact on Treatment Adherence</brief_title>
  <acronym>DACE</acronym>
  <official_title>Taking Into Account the Patient/Parent Preference in the Galenic Choice in Atopic Dermatitis. Feasibility and Impact on Treatment Adherence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic dermatitis is a chronic inflammatory skin disease often occurring in childhood.&#xD;
&#xD;
      The treatment consists in making daily local treatment with topical steroid on inflammatory&#xD;
      lesions and emollient on the whole body. However, approximately 70% of patients do not adhere&#xD;
      to therapy.&#xD;
&#xD;
      Studies have shown that this treatment failure is caused by the complexity of the treatment,&#xD;
      the time required for its implementation, the cost of treatment, the dosage of the products,&#xD;
      fear of side effects or misunderstanding about the chronicity of these diseases inflammatory&#xD;
      conditions of the skin.&#xD;
&#xD;
      This study aims to evaluate the consideration of patient preference in the choice of&#xD;
      excipient used for the topical treatment of eczema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Day 0 :&#xD;
&#xD;
        -  Inclusion, collecting non-opposition&#xD;
&#xD;
        -  Presentation of the samples: 4 products presented in the same packaging (pump bottle 200&#xD;
           ml) and ranked in order of their fat content:&#xD;
&#xD;
        -  Cold Cream: 88%&#xD;
&#xD;
        -  Modified Cerat Galen (national formulary): 66%&#xD;
&#xD;
        -  Cold Cream Fluid: 32%&#xD;
&#xD;
        -  Ointment: 21% The 4 products are all equally effective and suited in the treatment of&#xD;
           atopic dermatitis.&#xD;
&#xD;
      The patient choose the cream it will apply from 4 presented. A total of two bottles will be&#xD;
      given to the patient. A bottle containing only the emollient applied to dry areas and another&#xD;
      bottle in which 30% will be added Diprosone (topical steroid) to be applied on areas of&#xD;
      eczema).&#xD;
&#xD;
        -  Remitting the questionnaires&#xD;
&#xD;
        -  Severity scoring of atopic dermatitis (SCORAD)&#xD;
&#xD;
      Day 30:&#xD;
&#xD;
        -  Remitting the questionnaires&#xD;
&#xD;
        -  Treatments delivery for 2 months&#xD;
&#xD;
        -  SCORAD / PO SCORAD&#xD;
&#xD;
        -  Treatment weighing&#xD;
&#xD;
      Day 90:&#xD;
&#xD;
        -  SCORAD / PO-SCORAD&#xD;
&#xD;
        -  Treatments weighing&#xD;
&#xD;
        -  Remitting the final questionnaire&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2014</start_date>
  <completion_date type="Actual">October 31, 2015</completion_date>
  <primary_completion_date type="Actual">September 30, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the feasibility of giving the choice to the patient/parent of different galenic in atopic dermatitis.</measure>
    <time_frame>90 days</time_frame>
    <description>Assess the feasibility of giving the choice to the patient/parent of different galenic in atopic dermatitis.&#xD;
The primary outcome is evaluated through a questionnaire given to the patient/parent at day 0 day 30 day 90.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of this procedure in patient adherence to treatment (trough weighing treatments at day 30 and day 90)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of this procedure on the evolution of the disease</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluate the impact of this procedure on the evolution of the disease (trough SCORAD and PO-SCORAD at day 0, day 30, day 90)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the feasibility point of view of the prescribing physician</measure>
    <time_frame>90 days</time_frame>
    <description>- Assess the feasibility point of view of the prescribing physician (through questionnaires at day 0 day 30 day 90)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring the characteristics of a specified product and those of a product chosen by the patient</measure>
    <time_frame>90 days</time_frame>
    <description>- Measuring the characteristics of a specified product and those of a product chosen by the patient (through questionnaires at day 0, day 30, day 90)</description>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Atopic Dermatitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Multicenter prospective nonrandomized uncontrolled open-label study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients experiencing treatment failure despite appropriate treatment. Patients minors aged&#xD;
        between 3 and 15 years For children age 7 and non-autonomous children in the application of&#xD;
        treatment, the parent at the initial consultation should be the one who treats the child.&#xD;
&#xD;
        Information from both parents or parental authority and collection of Non-Opposition The&#xD;
        patient must have a computer to do its PO-SCORAD between consultations. Patient who used a&#xD;
        topical treatment for atopic dermatitis in the week preceding the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient refusal to participate in the clinical study. Adults and children over 15 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Fran√ßois Stalder, PU-PH</last_name>
    <role>Study Director</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marc Chavigny, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Pasteur Dermatologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.decas.univ-nantes.fr/GET/GET/POSCORAD_files/Po-Scorad_FR.pdf</url>
    <description>PO SCORAD</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2014</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis, Feasibility, Adherence to treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

